Cargando…

Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators

BACKGROUND: In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Muratov, Sergei, Canelo-Aybar, Carlos, Tarride, Jean-Eric, Alonso-Coello, Pablo, Dimitrova, Nadya, Borisch, Bettina, Castells, Xavier, Duffy, Stephen W., Fitzpatrick, Patricia, Follmann, Markus, Giordano, Livia, Hofvind, Solveig, Lebeau, Annette, Quinn, Cecily, Torresin, Alberto, Vialli, Claudia, Siesling, Sabine, Ponti, Antonio, Giorgi Rossi, Paolo, Schünemann, Holger, Nyström, Lennarth, Broeders, Mireille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444070/
https://www.ncbi.nlm.nih.gov/pubmed/32831048
http://dx.doi.org/10.1186/s12885-020-07289-z
_version_ 1783573733607211008
author Muratov, Sergei
Canelo-Aybar, Carlos
Tarride, Jean-Eric
Alonso-Coello, Pablo
Dimitrova, Nadya
Borisch, Bettina
Castells, Xavier
Duffy, Stephen W.
Fitzpatrick, Patricia
Follmann, Markus
Giordano, Livia
Hofvind, Solveig
Lebeau, Annette
Quinn, Cecily
Torresin, Alberto
Vialli, Claudia
Siesling, Sabine
Ponti, Antonio
Giorgi Rossi, Paolo
Schünemann, Holger
Nyström, Lennarth
Broeders, Mireille
author_facet Muratov, Sergei
Canelo-Aybar, Carlos
Tarride, Jean-Eric
Alonso-Coello, Pablo
Dimitrova, Nadya
Borisch, Bettina
Castells, Xavier
Duffy, Stephen W.
Fitzpatrick, Patricia
Follmann, Markus
Giordano, Livia
Hofvind, Solveig
Lebeau, Annette
Quinn, Cecily
Torresin, Alberto
Vialli, Claudia
Siesling, Sabine
Ponti, Antonio
Giorgi Rossi, Paolo
Schünemann, Holger
Nyström, Lennarth
Broeders, Mireille
author_sort Muratov, Sergei
collection PubMed
description BACKGROUND: In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection. METHODS: The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries. RESULTS: A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate. CONCLUSION: This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.
format Online
Article
Text
id pubmed-7444070
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74440702020-08-26 Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators Muratov, Sergei Canelo-Aybar, Carlos Tarride, Jean-Eric Alonso-Coello, Pablo Dimitrova, Nadya Borisch, Bettina Castells, Xavier Duffy, Stephen W. Fitzpatrick, Patricia Follmann, Markus Giordano, Livia Hofvind, Solveig Lebeau, Annette Quinn, Cecily Torresin, Alberto Vialli, Claudia Siesling, Sabine Ponti, Antonio Giorgi Rossi, Paolo Schünemann, Holger Nyström, Lennarth Broeders, Mireille BMC Cancer Research Article BACKGROUND: In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection. METHODS: The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries. RESULTS: A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate. CONCLUSION: This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality. BioMed Central 2020-08-24 /pmc/articles/PMC7444070/ /pubmed/32831048 http://dx.doi.org/10.1186/s12885-020-07289-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Muratov, Sergei
Canelo-Aybar, Carlos
Tarride, Jean-Eric
Alonso-Coello, Pablo
Dimitrova, Nadya
Borisch, Bettina
Castells, Xavier
Duffy, Stephen W.
Fitzpatrick, Patricia
Follmann, Markus
Giordano, Livia
Hofvind, Solveig
Lebeau, Annette
Quinn, Cecily
Torresin, Alberto
Vialli, Claudia
Siesling, Sabine
Ponti, Antonio
Giorgi Rossi, Paolo
Schünemann, Holger
Nyström, Lennarth
Broeders, Mireille
Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
title Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
title_full Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
title_fullStr Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
title_full_unstemmed Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
title_short Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
title_sort monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444070/
https://www.ncbi.nlm.nih.gov/pubmed/32831048
http://dx.doi.org/10.1186/s12885-020-07289-z
work_keys_str_mv AT muratovsergei monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT caneloaybarcarlos monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT tarridejeaneric monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT alonsocoellopablo monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT dimitrovanadya monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT borischbettina monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT castellsxavier monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT duffystephenw monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT fitzpatrickpatricia monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT follmannmarkus monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT giordanolivia monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT hofvindsolveig monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT lebeauannette monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT quinncecily monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT torresinalberto monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT vialliclaudia monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT sieslingsabine monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT pontiantonio monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT giorgirossipaolo monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT schunemannholger monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT nystromlennarth monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT broedersmireille monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators
AT monitoringandevaluationofbreastcancerscreeningprogrammesselectingcandidateperformanceindicators